Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine

Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine Abstract Of 14 patients taking tetrahydroaminoacridine (THA) for the trial treatment of Alzheimer's disease, five developed mildly abnormal liver function tests. Four asymptomatic patients with persistently abnormal serum transaminase levels underwent liver biopsy, in order to determine the nature of the hepatic lesions. One subject had granulomatous hepatitis while three showed focal, predominantly centrilobular, liver cell necrosis and mild fatty change. One of the latter showed both tissue and peripheral blood eosinophilia. The liver function tests of the fifth patient, who was symptomatic, became normal after reduction of the dose of THA so he did not undergo biopsy. These findings suggest that the pathogenic mechanisms for THA‐induced liver injury are heterogeneous ranging from hypersensitivity reactions to direct injury, and including combinations of the two. Patients receiving THA for treatment of Alzheimer's disease need regular monitoring of liver function. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Internal Medicine Journal Wiley

Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine

Download PDF
3 pages

Loading next page...
 
/lp/wiley/heterogeneity-of-adverse-hepatic-reactions-to-tetrahydroaminoacridine-h8qtwK2CaJ

References (9)

Publisher
Wiley
Copyright
Copyright © 1990 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1444-0903
eISSN
1445-5994
DOI
10.1111/j.1445-5994.1990.tb01309.x
Publisher site
See Article on Publisher Site

Abstract

Abstract Of 14 patients taking tetrahydroaminoacridine (THA) for the trial treatment of Alzheimer's disease, five developed mildly abnormal liver function tests. Four asymptomatic patients with persistently abnormal serum transaminase levels underwent liver biopsy, in order to determine the nature of the hepatic lesions. One subject had granulomatous hepatitis while three showed focal, predominantly centrilobular, liver cell necrosis and mild fatty change. One of the latter showed both tissue and peripheral blood eosinophilia. The liver function tests of the fifth patient, who was symptomatic, became normal after reduction of the dose of THA so he did not undergo biopsy. These findings suggest that the pathogenic mechanisms for THA‐induced liver injury are heterogeneous ranging from hypersensitivity reactions to direct injury, and including combinations of the two. Patients receiving THA for treatment of Alzheimer's disease need regular monitoring of liver function.

Journal

Internal Medicine Journal – Wiley

Published: Apr 1, 1990

Keywords: ; ;

There are no references for this article.